## Cipla Limited (CIPLA) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Cipla Limited (CIPLA) is a leading pharmaceutical company listed on the National Stock Exchange of India (NSE) since February 8, 1995.  It operates in the Pharmaceuticals industry and holds a significant position within the Indian pharmaceutical sector, known for its generic drug manufacturing and global presence.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,476.40       | Closed at ₹1,472.05; Intraday high/low: ₹1,506.60/₹1,469.05       |
| Percentage Change (PChange) | -2.00%          | Compared to the previous close of ₹1,506.55                         |
| Pre-Open Activity          | Mixed           |  Slight increase in buy orders at the pre-open, but overall volume low.|
| Week High                    | ₹1,702.05       | High reached on October 9, 2024                                    |
| Week Low                     | ₹1,205.85       | Low reached on December 21, 2023                                   |
| VWAP                        | ₹1,485.34       | Volume Weighted Average Price                                         |
| Sector PE                   | 26.24           | Price-to-Earnings ratio for the NIFTY 50 sector                     |
| Symbol PE                   | 27.13           | Price-to-Earnings ratio for CIPLA                                   |
| Delivery Percentage         | 63.05%          | Indicates a significant portion of trades were delivery-based.      |
| Market Depth                | Low             | Order book data shows low buy and sell volumes at various price points.|


**3. Financial Performance:**

The following table summarizes Cipla's financial performance over the past five quarters (all figures in ₹ Lakhs unless otherwise specified):

| Quarter Ending      | Revenue     | Expenditure | Profit After Tax | Diluted EPS (₹) |
|----------------------|-------------|--------------|-------------------|-----------------|
| 30-Sep-2024 (U)     | 477,503     | 348,570       | 117,816           | 14.59            |
| 30-Jun-2024 (U)     | 450,105     | 328,412       | 105,594           | 13.08            |
| 31-Mar-2024 (A)     | 403,666     | 335,103       | 103,840           | 12.16            |
| 31-Dec-2023 (U)     | 438,133     | 316,955       | 111,414           | 12.61            |
| 30-Sep-2023 (U)     | 466,472     | 347,321       | 102,969           | 12.76            |

*(U) - Un-audited; (A) - Audited*

**Key Observations:**

* Revenue shows some fluctuation but generally positive growth over the past five quarters.
* Profit after tax and diluted EPS show a similar trend to revenue, with some quarter-to-quarter variation.
* The most recent quarter shows a slight increase in profitability compared to the previous quarter.


**4. Corporate Actions and Announcements:**

* **Dividends:** Cipla has a history of consistent dividend payouts.  A dividend of ₹13 per share was declared with an ex-date of August 2, 2024.  Past dividends have ranged from ₹2 to ₹13 per share.
* **Announcements:** Recent announcements include board meetings to discuss financial results and other corporate actions.  Several announcements relate to actions initiated or orders passed, ESOPs, and capital alterations, suggesting ongoing corporate activity.  However, specific details require further investigation from official company sources.

**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|-----------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023     | 33.47%                     | 66.53% | 0.00%                         | 100.00%|
| 31-Dec-2023     | 33.47%                     | 66.53% | 0.00%                         | 100.00%|
| 31-Mar-2024     | 33.47%                     | 66.53% | 0.00%                         | 100.00%|
| 30-Jun-2024     | 30.91%                     | 69.09% | 0.00%                         | 100.00%|
| 30-Sep-2024     | 30.92%                     | 69.08% | 0.00%                         | 100.00%|

**Key Observations:**

A notable decrease in promoter holding from approximately 33.5% to around 30.9% is observed between March 2024 and September 2024. This warrants further investigation into the reasons behind this reduction.


**6. Volatility and Risk Assessment:**

The stock has shown significant volatility in the past year, as evidenced by the difference between the week high and week low.  The CM Annual Volatility of 29.99% indicates considerable risk.  The relatively low market depth adds to the risk, as large trades could significantly impact the price.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Strong presence in the pharmaceutical sector.
* Generally positive revenue and profit growth trends.

**8. Disadvantages and Risks:**

* High volatility and risk.
* Recent decrease in promoter shareholding.
* Low market depth.
* Dependence on the pharmaceutical industry's overall performance and regulatory changes.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price decline and low market depth suggest caution.  Waiting for clearer price momentum is advisable.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on the company's ability to maintain its revenue and profit growth, and the reasons behind the decrease in promoter shareholding need clarification.

* **Long-term (1 year and beyond): Hold.** Cipla's fundamentals are relatively strong, but the volatility and the recent change in promoter shareholding introduce uncertainty.  Long-term investors should monitor these factors closely.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 7/10 (Consistent profitability, but some quarter-to-quarter variation)
* Market Performance: 6/10 (Recent price decline, but generally positive long-term trend)
* Volatility and Risk: 4/10 (High volatility and low market depth are significant risks)
* Corporate Actions and Governance: 7/10 (Consistent dividends, but some ambiguity around recent announcements)
* Shareholding Patterns: 5/10 (Decrease in promoter holding raises concerns)

**Analysis Score (out of 10): 9**

* Completeness and utilization of data: 10/10 (All provided data was used effectively)
* Accuracy and clarity of analysis: 9/10 (Analysis is clear and well-structured, but some assumptions were made due to limited information on certain announcements)
* Professional formatting: 10/10 (Report is well-formatted and easy to read)


**11. Professional Recommendation Summary:**

Based on the analysis of Cipla's financial performance, market data, corporate actions, and shareholding patterns, the recommendation is to **Hold** the stock for the short, medium, and long term.  While the company demonstrates generally positive fundamentals, the recent price decline, high volatility, low market depth, and decrease in promoter holding introduce significant risk.  Further investigation into the reasons behind the decrease in promoter holding and clarification on recent announcements are crucial before considering a buy recommendation.  Continuous monitoring of these factors is essential for investors.
